HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 2,880.00
-65.00 (-2.21%)
At close: Feb 6, 2026
HLB Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -7,991 | -22,793 | -2,302 | -11,354 | -17,197 | -16,902 |
Depreciation & Amortization | 5,980 | 8,092 | 8,479 | 1,666 | 1,701 | 700.54 |
Loss (Gain) From Sale of Assets | -740.98 | 17.69 | -4.04 | 598.18 | 14.8 | -4.18 |
Asset Writedown & Restructuring Costs | 2,242 | 8,037 | 131.7 | 424.08 | 4,632 | 1,953 |
Loss (Gain) From Sale of Investments | -4,825 | 11,678 | -9,898 | 4.14 | 10.25 | -13.53 |
Loss (Gain) on Equity Investments | 3,850 | 433.03 | 1,406 | -1,883 | 349.23 | 909.06 |
Stock-Based Compensation | 768.18 | 813.12 | 213.52 | -83.89 | 153.28 | 471.17 |
Provision & Write-off of Bad Debts | 659.83 | 342.66 | -277.22 | -543.03 | -301.32 | 1,239 |
Other Operating Activities | 1,941 | -3,475 | 1,496 | 5,645 | 470.42 | 2,899 |
Change in Accounts Receivable | -5,275 | 762.96 | -1,135 | 1,355 | -1,659 | 2,876 |
Change in Inventory | 359.97 | 773.08 | 1,356 | -2,910 | 891.62 | 74 |
Change in Accounts Payable | 2,521 | -3,366 | 951.82 | 605.91 | -1,605 | -6,459 |
Change in Other Net Operating Assets | 6,626 | -28.79 | 2,909 | -2,332 | 1,273 | 605.53 |
Operating Cash Flow | 6,117 | 1,288 | 3,327 | -8,809 | -11,268 | -11,651 |
Operating Cash Flow Growth | - | -61.29% | - | - | - | - |
Capital Expenditures | -1,295 | -636.97 | -301.76 | -3,396 | -822.87 | -85.54 |
Sale of Property, Plant & Equipment | 74.99 | 46.06 | 2,596 | 216.25 | 40.91 | 66.45 |
Cash Acquisitions | - | - | - | -3,008 | - | - |
Divestitures | - | - | 5,915 | - | - | - |
Sale (Purchase) of Intangibles | -10,304 | -8,099 | -5,458 | -2,192 | -3,110 | -7,984 |
Investment in Securities | 3,948 | -26,740 | -24,133 | -30,370 | 18,872 | -9,793 |
Other Investing Activities | 1,345 | -27.32 | 1,220 | -3,409 | -697.5 | -5.78 |
Investing Cash Flow | -6,231 | -35,457 | -20,160 | -41,930 | 14,353 | -17,580 |
Long-Term Debt Issued | - | 26,000 | - | - | 65,000 | 6,332 |
Total Debt Issued | 21,000 | 26,000 | - | - | 65,000 | 6,332 |
Short-Term Debt Repaid | - | - | -3,118 | -755 | - | - |
Long-Term Debt Repaid | - | -7,114 | -15,096 | -2,556 | -22,146 | -6,399 |
Total Debt Repaid | -4,677 | -7,114 | -18,214 | -3,311 | -22,146 | -6,399 |
Net Debt Issued (Repaid) | 16,323 | 18,886 | -18,214 | -3,311 | 42,854 | -67.01 |
Issuance of Common Stock | 39.72 | 10,160 | 13,018 | - | 40,000 | 34.58 |
Repurchase of Common Stock | -797.99 | -636.17 | -70.12 | - | - | - |
Other Financing Activities | -14.74 | -15.69 | -14.59 | -7.08 | -0 | - |
Financing Cash Flow | 15,550 | 28,394 | -5,281 | -3,318 | 82,854 | -32.43 |
Foreign Exchange Rate Adjustments | 38.71 | 0.3 | 1.6 | 4.98 | 3.85 | -4.3 |
Net Cash Flow | 15,475 | -5,775 | -22,112 | -54,052 | 85,943 | -29,268 |
Free Cash Flow | 4,823 | 650.79 | 3,025 | -12,204 | -12,091 | -11,736 |
Free Cash Flow Growth | - | -78.49% | - | - | - | - |
Free Cash Flow Margin | 7.63% | 1.19% | 5.75% | -28.78% | -27.74% | -27.34% |
Free Cash Flow Per Share | 57.51 | 7.86 | 38.84 | -179.37 | -196.99 | -205.09 |
Cash Interest Paid | - | 100 | - | -28.3 | 1,261 | 664.71 |
Cash Income Tax Paid | 22.53 | 174.67 | -33.08 | 127.17 | 40.68 | -44.97 |
Levered Free Cash Flow | 11,602 | -9,511 | 7,272 | -14,458 | -12,654 | -18,101 |
Unlevered Free Cash Flow | 12,869 | -8,283 | 7,967 | -11,241 | -11,929 | -15,442 |
Change in Working Capital | 4,233 | -1,859 | 4,082 | -3,282 | -1,099 | -2,903 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.